glp-1-based therapy Redefining Obesity Management: Beyond GLP-1 Monotherapy 🩺 The therapeutic landscape for obesity and Type 2 Diabetes is evolving rapidly with the emergence of dual-hormone agonists. While semaglutide (GLP-1 RA) has demonstrated landmark GLP-1 Therapy for Diabetes and

Iron metabolism and the role of iron therapy in pediatric restless leg syndrome

April Jorge, quoted from ACR 2024 In a recent study, by Dr

This older group of patients should be closely monitored during treatment with valproic acid for the development of acute liver injury with regular clinical assessments and serum liver test monitoring

Consistent with this, whole-body GIP receptor deficiency and GIP deficiency protect against obesity induced by long-term high fat feeding in mice [65, 66]

J Pharm BioMed Anal (2021) 197:113971

Ice the treated area for 15-20 minutes and remain in-clinic for observation (15-30 minutes)